dc.contributor.author | Ramsay, Craig R | |
dc.contributor.author | Adewuyi, Temitope E | |
dc.contributor.author | Gray, Joanne | |
dc.contributor.author | Hislop, Jenni | |
dc.contributor.author | Shirley, Mark Df | |
dc.contributor.author | Jayakody, Shalmini | |
dc.contributor.author | MacLennan, Graeme | |
dc.contributor.author | Fraser, Cynthia | |
dc.contributor.author | MacLennan, Sara | |
dc.contributor.author | Brazzelli, Miriam | |
dc.contributor.author | N'Dow, James | |
dc.contributor.author | Pickard, Robert | |
dc.contributor.author | Robertson, Clare | |
dc.contributor.author | Rothnie, Kieran | |
dc.contributor.author | Rushton, Stephen P | |
dc.contributor.author | Vale, Luke | |
dc.contributor.author | Lam, Thomas B | |
dc.date.accessioned | 2015-07-28T13:30:02Z | |
dc.date.available | 2015-07-28T13:30:02Z | |
dc.date.issued | 2015-07-01 | |
dc.identifier | 52862619 | |
dc.identifier | fced5359-35f7-494e-88a9-2f0a1e9b14cd | |
dc.identifier | 26140518 | |
dc.identifier | 84934948929 | |
dc.identifier.citation | Ramsay , C R , Adewuyi , T E , Gray , J , Hislop , J , Shirley , M D , Jayakody , S , MacLennan , G , Fraser , C , MacLennan , S , Brazzelli , M , N'Dow , J , Pickard , R , Robertson , C , Rothnie , K , Rushton , S P , Vale , L & Lam , T B 2015 , ' Ablative therapy for people with localised prostate cancer : a systematic review and economic evaluation ' , Health Technology Assessment , vol. 19 , no. 49 , pp. 1-524 . https://doi.org/10.3310/hta19490 | en |
dc.identifier.issn | 1366-5278 | |
dc.identifier.other | ORCID: /0000-0003-1405-6964/work/61510997 | |
dc.identifier.other | ORCID: /0000-0003-4043-7349/work/84131300 | |
dc.identifier.other | ORCID: /0000-0002-1039-5646/work/98038493 | |
dc.identifier.uri | http://hdl.handle.net/2164/4713 | |
dc.description | The research reported in this issue of the journal was funded by the HTA programme as project number 10/136/01. The contractual start date was in April 2012. The draft report began editorial review in October 2013 and was accepted for publication in April 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Acknowledgements We thank l the people recruited from the local UCAN for providing valuable consumer insight and advice through their participation as members of the project focus group: - Mark Emberton (Professor of Interventional Oncology), Damian Greene (consultant urologist), Axel Heidenreich (Professor and Director of Department of Urology), Christoph von Klot (specialist in brachytherapy), Roger Kockelbergh (BAUS chairman and Clinical Director of Urology) and Axel Merserburger (Deputy Clinical Director of Urology and Urologic Oncology) for providing their clinical expertise as members of the project advisory group - Edgar Paez (consultant urologist) and Gill Lawrence (Head of Radiotherapy Physics) for providing a list of staff time by grade and specialty involved in EBRT - Debbie Bennett (Radiotherapy Service Manager) for providing estimates for the expected number of uses for EBRT - Ian Pedley (clinical director/clinical oncologist) and Gill Lawrence for providing a list of all resource inputs relevant to brachytherapy - Steve Locks (Consultant Clinical Scientist in Radiotherapy) for providing a list of reusable equipment and consumables used during brachytherapy, along with their unit costs - Sue Asterling (urology research nurse) and Mark Kelly (Acting Divisional General Manager – Theatres) for providing a list of all resource inputs relevant to cryotherapy - Lara Kemp for providing secretarial support. The Health Services Research Unit is core funded by the Chief Scientist Office of the Scottish Government Health Directorates. | en |
dc.format.extent | 524 | |
dc.format.extent | 5657400 | |
dc.language.iso | eng | |
dc.relation.ispartof | Health Technology Assessment | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | R Medicine | en |
dc.subject | National Institute for Health Research (NIHR) | en |
dc.subject | 10/136/01 | en |
dc.subject | Chief Scientist Office (CSO) | en |
dc.subject.lcc | R | en |
dc.title | Ablative therapy for people with localised prostate cancer : a systematic review and economic evaluation | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Health Services Research Unit | en |
dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Academic Urology Unit | en |
dc.description.status | Peer reviewed | en |
dc.identifier.doi | 10.3310/hta19490 | |
dc.identifier.vol | 19 | en |
dc.identifier.iss | 49 | en |